VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer

References

• Shushanov S, Bronstein M, Adelaide J, Jussila L, Tchipysheva T, Jacquemier J, Stavrovskaya A, Birnbaum D, Karamysheva A. VEGFc and VEGFR3 in human thyroid pathologies. Int J Cancer. 2000;86:47–52.
   PubMed Web of Science ®Google Scholar
• Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, Cakir I, Bayram F, Kelestimur F. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2011;164:277–284. doi:10.1530/EJE-10-0967
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853–865.
   PubMed Web of Science ®Google Scholar
• Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Piophys Res Commun. 1991;181:902–906.
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312.
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, Péer J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;10:1024–1028.
   Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.
   PubMed Web of Science ®Google Scholar
• Sato K. Vascular endothelial growth factors and thyroid disorders. Endocrine J. 2001;48:635–646. doi:10.1507/endocrj.48.635
   PubMed Web of Science ®Google Scholar
• De la Torre NG, Buley I, Wass JAH, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviour. Endocr Relat Cancer. 2006;13:931–944. doi:10.1677/erc.1.01210
   PubMed Web of Science ®Google Scholar
• Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Path. 2007;88:271–277. doi:10.1111/j.1365-2613.2007.00533.x
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer. 1998;78(12):1573–1577.
   PubMed Web of Science ®Google Scholar
• Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Ryan EJ, O'Sullivan JN. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One. 2011;6(10):1–9. doi:10.1371/journal.pone.0027944
   Web of Science ®Google Scholar
• Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumor vasculogenesis. Br J Cancer. 2005;92:1182–1187. doi:10.1038/sj.bjc.6602476
   PubMed Web of Science ®Google Scholar
• Cabillic F, Bouet-Toussaint F, Toutirais O, Rioux-Leclercq N, Fergelot P, Dela Pintiere CT, Genetet N, Patard JJ, Catros-Quemener V. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp Immunol. 2006;146:518–523. doi:10.1111/j.1365-2249.2006.03212.x
   PubMed Web of Science ®Google Scholar
• Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G. Increased expression of the vascular endothelial growth factor is pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656–658. doi:10.1210/jc.86.2.656
   PubMed Web of Science ®Google Scholar
• Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11:8063–8069. doi:10.1158/1078-0432.CCR-05-0646
   PubMed Web of Science ®Google Scholar
• Vieira JM, Santos SRC, Espadinha Correira I., Vag Tibor, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 2005;153:701–709. doi:10.1530/eje.1.02009
   PubMed Web of Science ®Google Scholar
• Fenton C, Patel A, Dinauer C, Robie D, Tuttle M, Francis G. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349–357.
   PubMed Web of Science ®Google Scholar
• Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS. 2003;111:439–443. doi:10.1034/j.1600-0463.2003.t01-1-1110209.x
   PubMed Web of Science ®Google Scholar
• Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck. 1998;20:152–158.
   PubMed Web of Science ®Google Scholar
• Akslen LA, LiVolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol. 2000;31:439–442. doi:10.1038/modpathol.3800452
   PubMed Web of Science ®Google Scholar
• Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ, LiVolsi VA. Lymphatic and blood vessel density in the follicular patterned lesions in thyroid. Modern Pathology. Mod Pathol. 2005;18:1424–1431. doi:10.1038/modpathol.3800452
   PubMed Web of Science ®Google Scholar
• Frigugliettl CU, Mello ES, Castro IV, Filho GB, Alves VA. Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck. 2000;22(4):373–379. doi:10.1002/1097-0347(200007)22:4<373::AID-HED10>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Dhar DK, Kubota H, Kotoh T., Tabara H, Watanabe R, Tachibana M, Kohno H, Nagasue N. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am. J. Surg. 1998;176:442–447.
   PubMed Web of Science ®Google Scholar
• Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996;9:636–641.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol. 2006;146:189–196. doi:10.1111/j.1365-2249.2006.03215.x
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmocitoid dendritic cells in cancer immunity. Immunology. 2007;121:149–157. doi:10.1111/j.1365-2567.2007.02579.x
   PubMed Web of Science ®Google Scholar
• Vlaykova T, Gulubova M, Manolova I, Vlaykova D, Cirovski G. Expression level of VEGF and its association with tumor-infiltrating dendritic cells in primary hepatocellular carcinoma. Falk Symp. 2006;157:10–11.
   Google Scholar
• Dela Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, Fraulini C, Russo Rossi A, Riccardi A, Castoldi G. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology. 2005;68:276–284. doi: 10.1159/000086768
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother. 2007;56:761–770. doi:10.1007/s00262-006-0234-7
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Carroll RG, Coukos G. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. NatMed. 2004;10:950–958. doi:10.1038/nm1097
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G.Vascular leukocytes contribute to tumor vascularization. Blood. 2005;105:679–681. doi:10.1182/blood-2004-05-1906
   Google Scholar